IPHARMA ARIMADEX(1MG ANASTROZOLE/TAB=50TABS)

Active-Life: 4-6 hours

Drug Class: Anti-estrogen /competitive inhibitor (Oral)

Average Reported Dosage: 0.5-3.0 mg daily

Acne: No

Water Retention: None

Liver Toxic: Yes dosage dependent

Decreases HPTA function: No, the drug has been accredited with HPTA up-regulating effects.

Arimidex is an anti-estrogen type drug. It is usually provided in 0.5 MG tabs. The drug works in a non-steroid form by inhibiting the aromatase enzyme which converts testosterone and other androgens into estrogen. This means that there is less estrogen to cause female pattern fat deposits, gyno, and water retention. In medicine, Arimidex is utilized to treat prostate cancer. In sports chemistry, the drug has been employed as a means of preventing excessive estrogenic side effects during AAS use and to aid in creating a harder appearing musculature for competitive bodybuilders. Unlike Nolvadex, which simply block estrogen receptor-sites, this drug prevents or reduces estrogen production. Though some estrogen presence is noted as necessary for AAS to reach full effectiveness, too much can cause a layer of fat, water retention, and breast tissue growth potentially with tumors called gynecomastia or bitch tits. Arimidex has a 75-85% aromatization inhibition rate.

Males who experienced excessive aromatization of AAS or who were extremely estrogen sensitive usually utilized a dosage of 0.5-3.0 mg daily. In fact, most realized excellent estrogen control with only 0.5mg/d (mg daily). Women usually showed excellent lean appearances (even in their legs) with 0.5-1.0 mg daily. Arimidex has a very short active-life so 0.5 mg dosages were often taken 2-6 times daily at equal intervals. Stacking 10-30 mg of Nolvadex with 1.0 mg of Arimidex has resulted in a near "0" estrogen activity situation regardless of the AAS protocol utilized. Directly following an AAS cycle, estrogen control has also become a problem (during periods intended for re­establishing HPTA function). In this case, the dosage was reduced from a higher starting dosage to a low dosage that was continued for 7-14 days after AAS discontinuance. This protocol was considered necessary to assure clearing of AAS induced estrogen build-up.

Arimidex is indicated for adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. 
Arimidex is indicated for the first-line treatment of postmenopausal women with hormone receptor positive or hormone receptor unknown locally advanced or metastatic breast cancer.

Arimidex is indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy .